We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals

49 hedge funds and large institutions have $110M invested in Corbus Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

67% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 9

38% more capital invested

Capital invested by funds: $79.4M → $110M (+$30.6M)

23% more funds holding

Funds holding: 4049 (+9)

0.98% more ownership

Funds ownership: 0%0.98% (+0.98%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

60% less call options, than puts

Call options by funds: $1.7M | Put options by funds: $4.3M

Holders
49
Holders Change
+9
Holders Change %
+22.5%
% of All Funds
1.22%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
19
Increased
15
Reduced
9
Closed
9
Calls
$1.7M
Puts
$4.3M
Net Calls
-$2.6M
Net Calls Change
-$3.18M

CRBP Hedge Fund Activity: Q4 2016 in Review

49 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2016, worth a combined $110M — up 38% from $79.4M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new CRBP positions and 9 closed out — a net gain of 10 holders — while 15 added to existing stakes and 9 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $8.44M. The largest seller was Perceptive Advisors, cutting an estimated $11.1M.

  • 49 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2016, up from 40 in Q3 2016.
  • Funds reported $110M of Corbus Pharmaceuticals stock for Q4 2016, up 38% quarter-over-quarter.
  • 19 funds opened new Corbus Pharmaceuticals positions in Q4 2016 and 9 closed out, a net change of +10 holders.
  • The largest Corbus Pharmaceuticals buyer in Q4 2016 was Fidelity Investments, an estimated $8.44M added.
  • The largest Corbus Pharmaceuticals seller in Q4 2016 was Perceptive Advisors, an estimated $11.1M sold.

Based on aggregated 13F filings for Q4 2016.